Cephalon executives to join Arana board
This article was originally published in Scrip
Executive Summary
Four senior Cephalon executives have joined the board of Arana Therapeutics, following Cephalon's acquisition of a majority holding in the Australian antibody firm. They are chairman and CEO Dr Frank Baldino Jr, chief financial officer Kevin Buchi, chief scientific officer Dr Jeffry Vaught and chief medical officer Dr Lesley Russell. Dr Baldino has been appointed chairman to succeed Robin Beaumont, who will step down to become lead independent director. Gordon Black and Lincoln Chee have retired as non-independent directors from Arana's board.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.